A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

NCT02566759 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

110

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.

Conditions

Schizophrenia, Cerebellar Ataxia

Interventions

DRUG: TAK-831 Oral Suspension
DRUG: TAK-831 Placebo
DRUG: TAK-831 Tablet

Sponsor

Neurocrine Biosciences

Collaborators

[object Object]